NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00169169,Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00169169,,TERMINATED,Rituximab vs observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor risk diffuse large B-cell lymphoma.,NO,CD20-Positive Large B-Cell Lymphoma,DRUG: ACVBP|DRUG: ACE|DRUG: rituximab|PROCEDURE: Autologous stem cell transplant,- To compare event-free survival of patients randomized to receive Rituximab or no further therapy after HDT,- To compare response rate to induction treatments (ACVBP vs AC/ACE).|- To evaluate response rate at the end of treatment.|- To compare overall survival (ACVBP vs AC/ACE; Rituximab / nothing)|- To evaluate the safety and tolerability of Rituximab,,Lymphoma Study Association,,ALL,ADULT,PHASE3,430,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,LNH-98.3,1999-10,,2005-08,2005-09-15,,2005-09-15,"Hôpital Henri Mondor, Créteil, France|Hôpital Saint Louis, Paris, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Henri Becquerel, Rouen, France|CHRU de Nancy Brabois, Vandoeuvre-les-Nancy, France",
